AK4 Lentiviral Activation Particles (h): sc-416951-LAC
- Target species: human
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- AK4 Lentiviral Activation Particles (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- AK4 Lentiviral Activation Particles (h) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by AK4 Lentiviral Activation Plasmid (h) and AK4 Lentiviral Activation Plasmid (h2) target distinct regulatory regions of the AK4 promoter. One or both designs may be available
- Following transfection, gene activation efficiency can be assayed by WB, IF or IHC using antibody: AK4 Antibody (A-9): sc-271161
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AK4 Lentiviral Activation Particles (h) | sc-416951-LAC | 200 µl | $455.00 | |||
AK4 Lentiviral Activation Particles (h2) | sc-416951-LAC-2 | 200 µl | $455.00 |
Human AK4 encodes adenylate kinase 4, a mitochondrial enzyme that regulates adenine nucleotide homeostasis by catalyzing reversible phosphate transfer among AMP, ADP, and ATP. Through its role in maintaining cellular energy balance, AK4 influences mitochondrial metabolism, oxidative stress responses, and apoptosis-related processes that couple bioenergetic state to cell survival decisions. Altered AK4 expression has been associated with metabolic reprogramming and stress adaptation observed in multiple disease contexts, including cancer biology and tissue injury models. As a mitochondrial regulator, AK4 is frequently studied in pathways linked to hypoxia signaling, reactive oxygen species handling, and mitochondrial quality control.
AK4 Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient AK4 upregulation across a broader range of human cell types.
AK4 Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the AK4 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous AK4 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native AK4 genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.